Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans

Translational Research

Volumn 165, Issue 6, 2015, Pages 651-657

  Hernandez, Wenndy ^a   Aquino Michaels, Keston ^a   Drozda, Katarzyna ^a   Patel, Shitalban ^a   Jeong, Young ^a   Takahashi, Harumi ^a   Cavallari, Larisa H ^a,b   Perera, Minoli A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Abbreviations RNA ribonucleic acid; SNP single nucleotide polymorphism

Indexed keywords

CYTOCHROME P450 2C9; WARFARIN; ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN;

ADULT; AFRICAN AMERICAN; ARTICLE; DRUG CLEARANCE; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HOMOZYGOTE; HUMAN; INDIVIDUALIZATION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MIDDLE AGED; ORAL CLEARANCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; BLACK PERSON; ENZYMOLOGY; GENETICS; LIVER; PHARMACOGENETICS;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ANTICOAGULANTS; CYTOCHROME P-450 CYP2C9; FEMALE; HUMANS; LIVER; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; WARFARIN;

EID: 84929275482     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2014.11.006     Document Type: Article

References (25)

1. J.O. Miners, and D.J. Birkett Cytochrome P4502C9: an enzyme of major importance in human drug metabolism Br J Clin Pharmacol 45 1998 525 538
2. H. Takahashi, and H. Echizen Pharmacogenetics of warfarin elimination and its clinical implications Clin pharmacokinet 40 2001 587 603
3. M.A. Perera, L.H. Cavallari, and N.A. Limdi Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study Lancet 382 2013 790 796
4. L.H. Cavallari, D. Vaynshteyn, and K.M. Freeman CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C9∗8-mediated effects Pharmacogenet Genomics 23 2013 228 231
5. M.A. Perera, E. Gamazon, and L.H. Cavallari The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans Clin Pharmacol Ther 89 2011 408 415
6. P. Flicek, M.R. Amode, and D. Barrell Ensembl 2014 Nucleic Acids Res 42 2014 D749 D755
7. W. Hernandez, E.R. Gamazon, and K. Aquino-Michaels Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans Pharmacogenomics J 14 2014 223 228
8. H. Takahashi, T. Kashima, and S. Kimura Determination of unbound warfarin enantiomers in human plasma and 7-hydroxywarfarin in human urine by chiral stationary-phase liquid chromatography with ultraviolet or fluorescence and on-line circular dichroism detection J Chromatogr B Biomed Sci Appl 701 1997 71 80
9. H. Takahashi, T. Kashima, and Y. Nomizo Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes Clin Pharmacol Ther 63 1998 519 528
10. S.Y. Choi, K.H. Koh, and H. Jeong Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone Drug Metab Dispos 41 2013 263 269
11. T.D. Schmittgen, and K.J. Livak Analyzing real-time PCR data by the comparative C(T) method Nat Protoc 3 2008 1101 1108
12. C.L. Aquilante, M.T. Lobmeyer, T.Y. Langaee, and J.A. Johnson Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory Pharmacotherapy 24 2004 720 726
13. M.W. Hruska, R.F. Frye, and T.Y. Langaee Pyrosequencing method for genotyping cytochrome P450 CYP2C8 and CYP2C9 enzymes Clin Chem 50 2004 2392 2395
14. N.A. Rosenberg, L.M. Li, R. Ward, and J.K. Pritchard Informativeness of genetic markers for inference of ancestry Am J Hum Genet 73 2003 1402 1422
15. J.K. Pritchard, M. Stephens, and P. Donnelly Inference of population structure using multilocus genotype data Genetics 155 2000 945 959
16. J.D. Crawford, M.E. Terry, and G.M. Rourke Simplification of drug dosage calculation by application of the surface area principle Pediatrics 5 1950 783 790
17. D. Van Booven, S. Marsh, and H. McLeod Cytochrome P450 2C9-CYP2C9 Pharmacogenet Genomics 20 2010 277 281
18. M.C. Frith, U. Hansen, and Z. Weng Detection of cis-element clusters in higher eukaryotic DNA Bioinformatics 17 2001 878 889
19. E. Chan, A.J. McLachlan, and M. Pegg Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin Br J Clin Pharmacol 37 1994 563 569
20. R.K. Absher, M.E. Moore, and M.H. Parker Patient-specific factors predictive of warfarin dosage requirements Ann pharmacother 36 2002 1512 1517
21. A. Blann, J. Hewitt, F. Siddiqui, and D. Bareford Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0 Br J Haematol 107 1999 207 209
22. G.G. Gan, A. Teh, K.Y. Goh, H.T. Chong, and K.W. Pang Racial background is a determinant factor in the maintenance dosage of warfarin Int J Hematol 78 2003 84 86
23. N.A. Limdi, T.M. Beasley, and M.R. Crowley VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans Pharmacogenomics 9 2008 1445 1458
24. H.C. Yu, T.Y. Chan, J.A. Critchley, and K.S. Woo Factors determining the maintenance dose of warfarin in Chinese patients QJM 89 1996 127 135
25. F. Zhao, C. Loke, and S.C. Rankin Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose Clin Pharmacol Ther 76 2004 210 219